Syndax Pharmaceuticals (SNDX): Director bought ~$45K
Martin H. Jr. Huber, Director at Syndax Pharmaceuticals, bought ~$45K of Syndax Pharmaceuticals shares.
- ~$45K
- Approx. value · 5,000 sh @ $8.99
- 79K
- Holds after · shares reported
- Traded
- May 19, 2025
- Filed
- May 19, 2025
What stands out in this filing
- The purchase added 6.8% to the shares this insider held before it; the filing reports 79,000 shares afterwards.
- 5,000 shares at an average of $8.99 each, as reported on the form.
- 3 other insiders at SNDX also bought in the open market within 30 days.
Calculated by OQRO from this filing and the public records it holds. Facts about the record, not a reason for the trade and not a signal.
The story around this disclosure
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
- May 16, 2025InsiderOfficer purchased ~$106K of SNDX shares in the open market
- May 19, 2025 · this disclosureInsiderDirector purchased ~$45K of SNDX shares in the open market
What came next
- May 19, 2025InsiderDirector purchased ~$91K of SNDX shares in the open market
- Jul 16, 2025Insider · 2 peopleInsiders: 2 sales (~$82K)
- Aug 14, 2025InsiderDirector sold ~$273K of SNDX shares in the open market
- Aug 15, 2025InsiderDirector sold ~$298K of SNDX shares in the open market
- Aug 18, 2025InsiderDirector sold ~$304K of SNDX shares in the open market
- Sep 8, 2025Insider · Their largest sale since 2020CEO sold ~$2.58M of SNDX shares in the open market
How to read SEC Form 4
Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.
Full guide: What is an SEC Form 4?
What else is on file for Syndax Pharmaceuticals
For Syndax Pharmaceuticals, OQRO holds 2 insider filings (SEC Form 4 or Form 144) dated in the last 90 days.
These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its SNDX page.
How this filing works
Explore the data
Common questions
Which Syndax Pharmaceuticals (SNDX) insider traded, and how much?
Martin H. Jr. Huber, Director at Syndax Pharmaceuticals, bought ~$45K of Syndax Pharmaceuticals shares. 5,000 shares at $8.99, open market.
When did it happen, and when was it made public?
Traded: May 19, 2025. Filed: May 19, 2025.
What stands out in this filing?
The purchase added 6.8% to the shares this insider held before it; the filing reports 79,000 shares afterwards. 5,000 shares at an average of $8.99 each, as reported on the form. 3 other insiders at SNDX also bought in the open market within 30 days.
Is the dollar amount exact?
It is the number of shares multiplied by the price the insider reported on the form. A grant, a gift or an option exercise has no market price, so those show shares only.
Where does this information come from?
From the SEC Form 4, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.
What else has been disclosed about Syndax Pharmaceuticals recently?
For Syndax Pharmaceuticals, OQRO holds 2 insider filings (SEC Form 4 or Form 144) dated in the last 90 days. They are listed on the SNDX page.
Does this mean SNDX stock is a buy or a sell?
No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.
Is OQRO free?
Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.
Other disclosures at Syndax Pharmaceuticals
- SEC Form 4Oct 30, 2026
- SEC Form 144Oct 29, 2026
- SEC Form 13F-HRAug 14, 2026
- SEC Form 13F-HRAug 14, 2026
- SEC Form 13F-HRMay 15, 2026
- SEC Form 13F-HRMay 15, 2026
Everything OQRO holds on this company is on its SNDX page.
This is one filing. OQRO holds the rest
Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.
OQRO is free for everyone. No card, no trial
OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data
